Cobimetinib
About
Therapy type: Targeted therapy
Therapy strategy: MEK inhibition
Mappings
NCI Thesaurus: Cobimetinib (ncit:C68923)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib |